JNJ - Johnson & Johnson
| Previous close | 139.90 |
| Open | 139.65 |
| Bid | 138.78 x 800 |
| Ask | 139.15 x 800 |
| Day's range | 138.86 - 140.14 |
| 52-week range | 118.62 - 148.99 |
| Volume | 5,110,628 |
| Avg. volume | 6,561,220 |
| Market cap | 370.658B |
| Beta (3Y monthly) | 0.69 |
| PE ratio (TTM) | 25.80 |
| EPS (TTM) | 5.40 |
| Earnings date | 16 Jul 2019 |
| Forward dividend & yield | 3.60 (2.58%) |
| Ex-dividend date | 2019-02-25 |
| 1y target est | 145.44 |
- Reuters•14 minutes ago
India alleges big multinationals did not pass on tax benefits: source
Indian tax authorities have alleged that a number of big multinational companies have not passed on benefits from a tax cut to customers, a senior government official told Reuters. The official said, for example, that the tax authorities have alleged that U.S. consumer goods maker Procter & Gamble did not pass on more than $35 million in tax benefits which were meant to have gone to its customers. Separately, the authorities are also investigating South Korea's Samsung Electronics and U.S. drug maker Johnson & Johnson among others, the senior government official, speaking on condition of anonymity, said.
- Motley Fool•17 hours ago
Everything You Need to Know About Investing in Healthcare
The global demand for healthcare products and services will keep growing significantly. Here's your complete guide to finding the best healthcare stocks and ETFs.
- Zacks•20 hours ago
Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales
Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.
- Market Realist•yesterday
Exploring JNJ’s Key Oncology Assets in the First Quarter
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Imbruvica’s trendsIn the first quarter, Johnson & Johnson (JNJ) and AbbVie’s (ABBV) Imbruvica reported 40% YoY (year-over-year) growth in
Market Realist•2 days agoPharmaceutical Segment: A Key Revenue Driver for JNJ in Q1
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Financial performanceIn the first quarter, Johnson & Johnson’s (JNJ) Pharmaceutical segment reported 7.9% YoY (year-over-year) growth in worldwide
- Motley Fool•2 days ago
Prescription for Success?
Prescription drug sales, the future of Hulu, and more.
- Market Realist•2 days ago
JNJ’s Consumer Business: International Market Trends in Q1
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)OTC business performance in international markets In the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported a 3% YoY
Market Realist•2 days agoJNJ’s OTC, Oral Care, and Wound Care Businesses: Key Trends in Q1
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)OTC businessIn the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported revenue of $1.09 billion, reflecting YoY
- Market Realist•3 days ago
Beauty: A Key Growth Driver of JNJ’s Consumer Segment in Q1
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Financial performance In the first quarter, Johnson & Johnson’s (JNJ) Consumer segment reported 2.2% YoY (year-over-year) growth in worldwide
Market Realist•3 days agoWhat Are Analysts Recommending for Johnson & Johnson?
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Stock price movementsOn April 17, Johnson & Johnson (JNJ) closed at $138.52, 0.36% higher than its previous closing price, 16.78% higher than its
- Market Realist•3 days ago
JNJ or PFE: Comparing Legacy and Newly Launched Immunology Drugs
Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Legacy immunology drugs In the first quarter, Johnson & Johnson (JNJ) reported Remicade sales worth $1.10 billion, a YoY (year-over-year) fall of 20.6% on
- Market Realist•3 days ago
JNJ Surpassed Consensus Estimates in the First Quarter
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?Revenue performance Johnson & Johnson (JNJ) reported its earnings results for the first quarter of 2019 on April 16. In its first-quarter earnings press release, the company
- Market Realist•3 days ago
JNJ or PFE: Comparing Their Fastest-Growing Immunology Drugs
Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Immunology revenue performance In the first quarter, Johnson & Johnson (JNJ) reported immunology sales of $3.25 billion, a YoY (year-over-year) rise of
- Market Realist•3 days ago
JNJ or PFE: Which Has Better EPS Guidance for 2019?
Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)EPS guidance In its first-quarter earnings press release, Johnson & Johnson (JNJ) raised the guidance for its adjusted diluted operational EPS from its
Associated Press•4 days agoJohnson & Johnson posts strong revenue in 1Q
Lower sales overseas and higher costs for research and litigation pushed Johnson & Johnson's first-quarter profit down 14%, but the health care giant beat profit and revenue expectations, pushing up its ...
Associated Press•4 days agoAsian shares edge lower despite encouraging China GDP data
Major share benchmarks were mostly lower in Asia on Wednesday after China announced its economy grew at a 6.4% annual pace in the last quarter. Japan's Nikkei 225 index gained 0.3% to 22,289.32 and the ...
- Motley Fool•6 days ago
5 Top Pharmaceutical Stocks to Buy in 2019
Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.
- Zacks•7 days ago
Here Are the Key Takeaways From J&J's Q1 Earnings Report
Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
- Zacks•8 days ago
Stock Market News For Apr 17, 2019
Markets closed higher on Tuesday as investors welcomed a spate of healthy first quarter earnings results.
- Investing.com•8 days ago
StockBeat - UnitedHealth Deepens Losses as Fears Over Political Risk Rise
Investing.com - UnitedHealth Group fell deeper into the red Wednesday as analysts turned bearish on the stock in the wake of its CEO's warning on political risk.
- MarketWatch•8 days ago
5 takeaways from Johnson & Johnson’s first-quarter results
Johnson & Johnson topped Wall Street’s earnings expectations on Tuesday, extending the company’s multiyear streak of delivering better-than-expected results.
- Morningstar•8 days ago
Solid Drug Sales, Cost Control Boost Johnson & Johnson
The first-quarter performance reinforces our wide moat rating.
- Associated Press•8 days ago
US halts sales of pelvic mesh tied to injuries in women
WASHINGTON (AP) — U.S. health regulators on Tuesday halted sales of a type of surgical mesh used to repair pelvic conditions in women, following years of patients' reports of injuries and complications from the implants.
- Associated Press•9 days ago
Qualcomm and Progressive jump while Wave Life Sciences drops
Stocks that moved substantially or traded heavily on Tuesday: Qualcomm Corp., up $13.27 to $70.45 The mobile chip maker settled a long-running financial dispute with iPhone maker Apple. Johnson & Johnson, ...
- Motley Fool•9 days ago
What Happened in the Stock Market Today
Johnson & Johnson's earnings results were better than expected, and UnitedHealth Group reported strong growth but stirred investor angst.
